NEW Drs. Jeffrey and Isabel Chell Clinical Trials Travel Grant
As you may recall, NMDP/Be The Match received a generous
contribution from the Carter Family last year to continue their son Jason’s
legacy by helping to get more people to participate in clinical trials which
established the Jason Carter Clinical Trials Program. In partnership with the Jason Carter
Clinical Trials Program
(JCCTP), the Drs. Jeffrey and Isabel
Chell Clinical Trials Grant provides financial assistance to qualified
patients (blood disorders/cancers), who need help paying for travel, ground
transportation and lodging. If you have any questions, please contact our
Clinical Trial Patient Education Specialist by calling 1-888-814-8610 or email email@example.com.
Protect Medicare Patient Access to Life-Saving Transplants
Medicare patients need your help! Ask your Members of
Congress to support and cosponsor HR 4215,
the Protect Access to Cellular Transplant (PACT) Act, which would require the
Centers for Medicare & Medicaid Services (CMS) to reimburse for donor
search & cell acquisition on a reasonable cost basis and separate from the
MS-DRG payment that covers the inpatient stay. Transplant centers lose
thousands of dollars on every Medicare patient they treat, creating a
financially unsustainable environment and threatening patient access to
transplant. Ask your Members of Congress to support HR 4215.
HCT Guidelines for Referral Timing and Post-Transplant Care
Every year, the NMDP/Be The Match partners with the American
Society for Blood and Marrow Transplantation™ (ASBMT) to produce the most
up-to-date transplant referral guidelines based on current clinical practice,
medical literature, evidence-based reviews, and National Comprehensive Cancer Network®
(NCCN) guidelines. Access the updated guidelines to better understand the most appropriate timing for transplant referral resulting
in optimal patient outcomes and survival.
American Society of Hematology 2017 Annual Meeting Recap
If you couldn't attend ASH 2017 last month, here are
few noteworthy session highlights:
Cost-effectiveness Analysis of CTL019 for the
Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory
B-Cell Acute Lymphoblastic Leukemia in the United States
survival model was used to compare incremental cost-effectiveness of Kymriah
(CTL019) vs. other standard-of-care treatments. Over a 20-year time horizon,
treatment with Kymriah lead to an increase of 2.31 discounted QALYs relative to
HCT. Kymriah value prices set at incremental cost-effectiveness ratio
$150,000/QALY ranged from $604,289 to $779,487 across comparators. Review the abstract here.
Prevalence and Risk-Factors for Financial Burden
in Patients with Chronic Graft-Versus-Host Disease: A Cross-Sectional Survey
from the Chronic GVHD Consortium
questionnaire regarding financial burden topics was completed by 182 patients
enrolled on a multi-center observational study measuring outcomes for cGVHD
treatment. The authors conclude that significant proportion of cGVHD patients
are at risk for worse outcomes due to financial hardship. Review the abstract here.
Survival Outcome and Insurance Status Among
Hodgkin’s Lymphoma (HL) Patients: Data from SEER 2007-2014
Insurance is one of the most important determinants of
health disparity. A study on outcomes and insurance status among Hodgkin
Lymphoma patients shows that Medicaid patients had the worst outcomes in almost
all age groups. This study was performed
using data from years 2007-2014, prior to Medicaid expansion under the
Affordable Care Act. Review the abstract here.
Quality of Life of Informal Caregivers of
Hematopoietic Cell Transplant Recipients
Although transplant recipients are required to designate
informal caregivers, there are only a few small studies that seek to understand
levels of distress and burden on the caregiver. In the largest analysis of
caregiver QoL to date, the authors report that low caregiver QoL is associated
with recipient distress, relapse, use of immunosuppressive therapy, and lower
recipient QoL. Review the abstract here.
Forward to a Friend
Please forward this email to others who would benefit from this information. If this email was forwarded to you, we invite you to subscribe.
If you have any questions or need additional information, please contact the Payer Policy Team at PayerPolicy@nmdp.org. All of our resources are available on our website: Network.BeTheMatchClinical.org/Reimbursement.